CORRECTING and REPLACING Advanced Medical Optics Announces Partnership with Institute for Eye Research to Develop Contact Lens Disinfectant and Cleaning Solutions
Santa Ana, Calif. (BUSINESS WIRE) - In the release dated June 16, 2008, the URL at the end of the "About The Institute for Eye Research (IER)"section should read www.ier.org.au (sted www.ier.org).
The corrected release reads: ADVANCED MEDICAL OPTICS ANNOUNCES PARTNERSHIP WITH INSTITUTE FOR EYE RESEARCH TO DEVELOP CONTACT LENS DISINFECTANT AND CLEANING SOLUTIONS Advanced Medical Optics, Inc. (AMO) (NYSE: EYE), a global leader in ophthalmic surgical devices and eye care products, has announced a collaboration with the Institute for Eye Research (IER) to develop contact lens disinfectant and cleaning solutions and related products.
IER is a non-profit research organization that conducts collaborative and contract research with and for industry in the area of vision correction, eye care, the anterior eye, contact lenses, contact lens care and patient management, to avoid contact lens complications. The organization is a world leader in the in vitro and clinical evaluation of silicone hydrogel lenses and their interaction with contact lens care products using their proprietary modeling systems and databases.
"IER's world-class scientists and clinicians have had a major impact on the development of contact lenses and lens care technologies," said AMO Executive Vice President, Research and Development Leonard Borrmann. "We look forward to working closely with the IER on the development of next-generation contact lens solutions.""Through our collaboration with AMO, we will work to develop, test and deliver, through product innovation and education, the best in contact lens care products," said IER CEO Brien Holden, PhD. "Our goal is to develop new, safer, better and more convenient initiatives in the field of contactlenscleaning and disinfectionsystems, including the containers for storage, cleaning and disinfection."
IER is headquartered in Sydney, Australia.
About Advanced Medical Optics (AMO) AMO is focused on providing the full range of advanced refractive technologies and support to help eye care professionals deliver optimal vision and lifestyle experiences to patients of all ages. Products in the cataract line include monofocal intraocular lenses (IOLs), phacoemulsification systems, viscoelastics, and related products used in ocular surgery. AMO owns or has the rights to such product brands as Tecnis?, Clariflex? and Sensar? IOLs; Sovereign?, Sovereign? Compact and WhiteStar Signature? phacoemulsification systems with WhiteStar? technology; Healon? viscoelastics and the Baerveldt?glaucoma shunt. Products in the refractive line include wavefront diagnostic devices, femtosecond lasers and associated patient interface devices; excimer laser vision correction systems and treatment cards, and refractive implants. AMO brands in the refractive business include iDesign?, iFS?, Star S4 IR?, WaveScan Wavefront?, Advanced CustomVue?, IntraLase?, IntraLasik? and ReZoom?, Tecnis? Multifocal and Verisyse?IOLs.
Products in the eye care line include disinfecting solutions, enzymatic cleaners, lens rewetting drops and artificial tears. Among the eye care product brands the company possesses are COMPLETE?, COMPLETE? Blink-N-Clean?, Consept?F, Consept? 1 Step, Oxysept? 1 Step, UltraCare?, Ultrazyme?, Total Care? and blink?branded products. AMO is based in Santa Ana, California, and employs approximately 4,000 worldwide. The company has operations in 24 countries and markets products in approximately 60 countries. For more information, visit the company's Website at www.amo-inc.com.
About The Institute for Eye Research (IER) The Institute for Eye Research Limited is dedicated to the proposition of "Vision excellence for all people." For more than 20 years, the Institute has collaborated with the world's leading researchers to bring innovation in vision. An Australian not-for-profit organization, IER has grown to be a major participant and supporter of research worldwide and is committed to the advancement of vision science and the provision of sustainable eye care services and education in developing communities.
For more information please go to www.ier.org.au.
Forward-Looking Statements This press release contains forward-looking statements about AMO, including statements by Dr. Borrmann and Professor Holden and statements relating to development of next-generation contact lens care products.
All forward-looking statements in this press release represent AMO's judgment only as of the date of this press release. Actual results may differ from current expectations based on a number of factors, including, but not limited to, unexpected delays or costs associated with the research and development of testing standards and new formulas for contact lens care products, continued acceptance of our current products, and unexpected changes in competitive, regulatory and market conditions. Therefore, the reader is cautioned not to rely on these forward-looking statements. AMO disclaims any intent or obligation to update these forward-looking statements. Additional information concerning these and other risk factors may be found in previous press releases issued by AMO and AMO's public periodic filings with the Securities and Exchange Commission, including the discussion under the heading "Risk Factors" in AMO's 2007 Form 10-K filed in?March 2008.
Copies of press releases and additional information about AMO are available at www.amo-inc.com.
Advanced Medical Optics, Inc.Investors:Sheree
Aronson,Corporate Vice President,Investor Relations and
Corporate Communications 714-247-8290
sheree.aronson@amo-inc.com or Media:Steve Chesterman, Manager,
Corporate Communications 714-247-8711
steve.chesterman@amo-inc.com
Santa Ana, Calif. (BUSINESS WIRE) - In the release dated June 16, 2008, the URL at the end of the "About The Institute for Eye Research (IER)"section should read www.ier.org.au (sted www.ier.org).
The corrected release reads: ADVANCED MEDICAL OPTICS ANNOUNCES PARTNERSHIP WITH INSTITUTE FOR EYE RESEARCH TO DEVELOP CONTACT LENS DISINFECTANT AND CLEANING SOLUTIONS Advanced Medical Optics, Inc. (AMO) (NYSE: EYE), a global leader in ophthalmic surgical devices and eye care products, has announced a collaboration with the Institute for Eye Research (IER) to develop contact lens disinfectant and cleaning solutions and related products.
IER is a non-profit research organization that conducts collaborative and contract research with and for industry in the area of vision correction, eye care, the anterior eye, contact lenses, contact lens care and patient management, to avoid contact lens complications. The organization is a world leader in the in vitro and clinical evaluation of silicone hydrogel lenses and their interaction with contact lens care products using their proprietary modeling systems and databases.
"IER's world-class scientists and clinicians have had a major impact on the development of contact lenses and lens care technologies," said AMO Executive Vice President, Research and Development Leonard Borrmann. "We look forward to working closely with the IER on the development of next-generation contact lens solutions.""Through our collaboration with AMO, we will work to develop, test and deliver, through product innovation and education, the best in contact lens care products," said IER CEO Brien Holden, PhD. "Our goal is to develop new, safer, better and more convenient initiatives in the field of contactlenscleaning and disinfectionsystems, including the containers for storage, cleaning and disinfection."
IER is headquartered in Sydney, Australia.
About Advanced Medical Optics (AMO) AMO is focused on providing the full range of advanced refractive technologies and support to help eye care professionals deliver optimal vision and lifestyle experiences to patients of all ages. Products in the cataract line include monofocal intraocular lenses (IOLs), phacoemulsification systems, viscoelastics, and related products used in ocular surgery. AMO owns or has the rights to such product brands as Tecnis?, Clariflex? and Sensar? IOLs; Sovereign?, Sovereign? Compact and WhiteStar Signature? phacoemulsification systems with WhiteStar? technology; Healon? viscoelastics and the Baerveldt?glaucoma shunt. Products in the refractive line include wavefront diagnostic devices, femtosecond lasers and associated patient interface devices; excimer laser vision correction systems and treatment cards, and refractive implants. AMO brands in the refractive business include iDesign?, iFS?, Star S4 IR?, WaveScan Wavefront?, Advanced CustomVue?, IntraLase?, IntraLasik? and ReZoom?, Tecnis? Multifocal and Verisyse?IOLs.
Products in the eye care line include disinfecting solutions, enzymatic cleaners, lens rewetting drops and artificial tears. Among the eye care product brands the company possesses are COMPLETE?, COMPLETE? Blink-N-Clean?, Consept?F, Consept? 1 Step, Oxysept? 1 Step, UltraCare?, Ultrazyme?, Total Care? and blink?branded products. AMO is based in Santa Ana, California, and employs approximately 4,000 worldwide. The company has operations in 24 countries and markets products in approximately 60 countries. For more information, visit the company's Website at www.amo-inc.com.
About The Institute for Eye Research (IER) The Institute for Eye Research Limited is dedicated to the proposition of "Vision excellence for all people." For more than 20 years, the Institute has collaborated with the world's leading researchers to bring innovation in vision. An Australian not-for-profit organization, IER has grown to be a major participant and supporter of research worldwide and is committed to the advancement of vision science and the provision of sustainable eye care services and education in developing communities.
For more information please go to www.ier.org.au.
Forward-Looking Statements This press release contains forward-looking statements about AMO, including statements by Dr. Borrmann and Professor Holden and statements relating to development of next-generation contact lens care products.
All forward-looking statements in this press release represent AMO's judgment only as of the date of this press release. Actual results may differ from current expectations based on a number of factors, including, but not limited to, unexpected delays or costs associated with the research and development of testing standards and new formulas for contact lens care products, continued acceptance of our current products, and unexpected changes in competitive, regulatory and market conditions. Therefore, the reader is cautioned not to rely on these forward-looking statements. AMO disclaims any intent or obligation to update these forward-looking statements. Additional information concerning these and other risk factors may be found in previous press releases issued by AMO and AMO's public periodic filings with the Securities and Exchange Commission, including the discussion under the heading "Risk Factors" in AMO's 2007 Form 10-K filed in?March 2008.
Copies of press releases and additional information about AMO are available at www.amo-inc.com.
Advanced Medical Optics, Inc.Investors:Sheree
Aronson,Corporate Vice President,Investor Relations and
Corporate Communications 714-247-8290
sheree.aronson@amo-inc.com or Media:Steve Chesterman, Manager,
Corporate Communications 714-247-8711
steve.chesterman@amo-inc.com
No comments:
Post a Comment